PMID- 25216630
OWN - NLM
STAT- MEDLINE
DCOM- 20151203
LR  - 20211021
IS  - 1433-3023 (Electronic)
IS  - 0937-3462 (Linking)
VI  - 26
IP  - 3
DP  - 2015 Mar
TI  - Trigonal versus extratrigonal botulinum toxin-A: a systematic review and 
      meta-analysis of efficacy and adverse events.
PG  - 313-9
LID - 10.1007/s00192-014-2499-2 [doi]
AB  - INTRODUCTION AND HYPOTHESIS: Botulinum toxin-A (BoNT-A) is a potent neurotoxin 
      that is an effective treatment for patients with pharmacologically refractory 
      detrusor overactivity (DO). Data assessing the effectiveness of trigonal BoNT-A 
      are limited. This study evaluates adverse events (AEs) and short-term efficacy 
      associated with trigonal and extratrigonal BoNT-A. METHODS: Electronic databases 
      (PubMed, EMBASE, and the Cochrane database) were searched for studies comparing 
      trigonal and extratrigonal BoNT-A for DO. Meta-analyses were performed using the 
      random effects model. Outcome measures included incidence of AEs and short-term 
      efficacy. RESULTS: Six studies describing 258 patients met the inclusion 
      criteria. The meta-analysis did not show significant differences between trigonal 
      and extratrigonal BoNT-A for acute urinary retention (AUR; 4.2 vs 3.7 %; odds 
      ratio [OR]: 1.068, 95 % confidence interval [CI]: 0.239-4.773; P =  0.931) or 
      high post-void residual (PVR; 25.8 vs 22.2 %; OR: 0.979; 95 % CI: 0.459-2.088; 
      P =  0.956). The incidence of urinary tract infection (UTI; 7.5 vs 21.0 %; OR: 
      0.670; 95 % CI: 0.312-1.439; P =  0.305), haematuria (15.8 vs 25.9 %; OR: 0.547; 
      95 % CI: 0.264-1.134; P =  0.105) and post-operative muscle weakness (9.2 vs 11.3 
      %; OR: 0.587; 95 % CI: 0.205-1.680, P =  0.320) was similar in both groups. 
      Finally, differences in short-term cure rates between two study arms were not 
      statistically significant (52.9 vs 56.9 %; OR: 1.438; 95 % CI: 0.448-4.610; P =  
      0.542). CONCLUSIONS: Although data are limited, no significant differences 
      between trigonal and extratrigonal BoNT-A in terms of AEs and short-term efficacy 
      were observed. Additional randomised controlled trials are required to define 
      optimal injection techniques and sites for administering intra-vesical BoNT-A.
FAU - Davis, N F
AU  - Davis NF
AD  - Department of Urology, Mercy University Hospital, Cork City, Co Cork, Ireland, 
      nialldavis@rcsi.ie.
FAU - Burke, J P
AU  - Burke JP
FAU - Redmond, E J
AU  - Redmond EJ
FAU - Elamin, S
AU  - Elamin S
FAU - Brady, C M
AU  - Brady CM
FAU - Flood, H D
AU  - Flood HD
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20140913
PL  - England
TA  - Int Urogynecol J
JT  - International urogynecology journal
JID - 101567041
RN  - 0 (Acetylcholine Release Inhibitors)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Acetylcholine Release Inhibitors/*administration & dosage/*adverse effects
MH  - Administration, Intravesical
MH  - Botulinum Toxins, Type A/*administration & dosage/*adverse effects
MH  - Humans
MH  - Urinary Bladder, Overactive/*drug therapy
EDAT- 2014/09/14 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/09/14 06:00
PHST- 2014/06/15 00:00 [received]
PHST- 2014/08/24 00:00 [accepted]
PHST- 2014/09/14 06:00 [entrez]
PHST- 2014/09/14 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1007/s00192-014-2499-2 [doi]
PST - ppublish
SO  - Int Urogynecol J. 2015 Mar;26(3):313-9. doi: 10.1007/s00192-014-2499-2. Epub 2014 
      Sep 13.